Symptom resolution does not predict healing of erosive oesophagitis in Chinese

Digestion. 2007;75(2-3):128-34. doi: 10.1159/000106453. Epub 2007 Jul 13.

Abstract

Background: Previous studies suggested that Chinese have a milder spectrum of gastro-oesophageal reflux disease and a lower dose of proton pump inhibitors (PPI) is sufficient for the control of symptoms as compared with the Western population.

Aims: To determine if 8 weeks of esomeprazole 20 mg daily would be adequate for both symptom resolution and oesophagitis healing in Chinese patients and the predictive factors for the response.

Methods: 66 patients with oesophagitis were included. Oesophagitis severity was graded by Los Angeles (LA) classification. 61 patients underwent 24-hour ambulatory pH study at baseline. All were given esomeprazole 20 mg daily for 8 weeks. Symptom response and healing of oesophagitis was assessed at the end of the treatment period.

Results: 75.8% of the patients had complete reflux symptom resolution but only 48% had complete healing of the oesophagitis at endoscopy after 8 weeks of treatment. LA classification grading at baseline endoscopy (p < 0.0001) and total number acid reflux episodes on 24-hour pH monitoring prior to treatment (p = 0.007) were both good predictors of oesophagitis healing but not for symptom resolution.

Conclusions: Our results suggested that 8 weeks of lower dose PPI is not sufficient for oesophagitis healing. Symptom resolution with PPI does not predict oesophagitis healing in Chinese.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Ulcer Agents / therapeutic use*
  • Chi-Square Distribution
  • China
  • Esomeprazole / therapeutic use*
  • Esophagitis / drug therapy*
  • Esophagitis / ethnology*
  • Esophagoscopy
  • Female
  • Gastric Acidity Determination
  • Humans
  • Hydrogen-Ion Concentration
  • Logistic Models
  • Male
  • Manometry
  • Middle Aged
  • Risk Factors
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Anti-Ulcer Agents
  • Esomeprazole